[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

Understanding FLT3 in AML: What It Means and How It’s Treated

Understanding FLT3 in AML: What It Means and How It’s Treated image

Understanding FLT3 in AML: What It Means and How It’s Treated

Webinar
event May 15, 2025 / 03:00PM - 04:00PM EDT
link icon facebook logo X logo linkedin logo reddit logo email icon
videocam
Can't make it to the event?
We send a recording to all registered participants of the event!

Event Description

Join us for a special session focused on FLT3 mutations in Acute Myeloid Leukemia (AML), one of the most common genetic changes found in AML patients. Dr. Nicholas Short from MD Anderson Cancer Center will explain what FLT3 mutations are, how they affect treatment decisions, and what targeted therapies are available today. Whether you’re newly diagnosed or navigating ongoing treatment, this session will help you understand the role FLT3 plays in your AML journey and what questions to ask your doctor.

Schedule & Agenda

The panelist Marilú Nájera Flores
3:00 PM
Introduction
Marilú Nájera Flores

Marilu introduces the agenda for the event and featured speaker Dr. Nicholas Short

The panelist Dr Nicholas Short
3:05 PM
Presentation
Dr Nicholas Short

 

Dr. Short talks about FLT3 mutations in AML

The panelist Audience
3:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators

The panelist Marilú Nájera Flores
Marilú Nájera Flores

Marilu is an International Medical Graduate passionate about supporting patients and building strong community connections. Since joining HealthTree, she has contributed in roles such as Myeloma Navigator and Patient Navigator, always focused on empowering patients. Now, as Event Operations Manager, she organizes webinars featuring key speakers to address topics relevant to AML and MDS patients and their families. Beyond her work, Marilu is a travel enthusiast and a good listener who enjoys spending time with her family and friends.

Read Bio
The panelist Dr Nicholas Short
Dr Nicholas Short
University of Texas MD Anderson Cancer Center

Dr. Nicholas Short is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. He specializes in adult acute leukemias, with a focus on targeted therapies and measurable residual disease (MRD). Dr. Short leads numerous phase I and II clinical trials exploring new treatment options for AML and ALL. He has authored over 200 peer-reviewed publications and has presented his research at major conferences like ASH and ASCO. His work has earned him prestigious honors, including the ASCO Young Investigator Award and the ASH Junior Faculty Scholar Award.

Read Bio
HealthTree Connect Icon

Join the Conversation

This event is part of the Lab Values and Testing group in HealthTree Connect, a social media platform for people with blood cancer. If you want to connect with other patients and caregivers and talk about this topic, join HealthTree Connect.

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Kura Oncology logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.